For the Inventor, By the Inventor

Enter assignee name

Bethesda, MD, United States of America

Precision Biologics, Inc.

USPTO Granted Patents = 29

CIPO Patents = 5

EPO Patents = 6

Forward Citations = 92

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

J Andrew Bristol (13 out of 16 patents)

Kwong Y Tsang (12 out of 18 patents)

Myron Arlen (10 out of 15 patents)

4. Xue-Ping Wang (9 out of 10 patents)

5. Judith A Kantor (8 out of 18 patents)

6. Philip M Arlen (6 out of 6 patents)

7. Ariel C Hollinshead (6 out of 7 patents)

8. Xiulian Du (1 out of 1 patent)

9. Janos Luka (1 out of 1 patent)

10. Lewis Joe Stafford (1 out of 1 patent)

11. Mark Semenuk (1 out of 1 patent)

12. Andrew Bristol (1 out of 8 patents)

13. Massimo Fantini (1 out of 1 patent)

14. Justin M David (1 out of 1 patent)

15. Myren Arlen (0 patent)

29 patents: Sort by Forward Citations

1. 12460013 - Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers (2025-11-04),

2. 12454560 - Colon and pancreas cancer peptidomimetics (2025-10-28),

3. 12344676 - Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers (2025-07-01),

4. 12037410 - Methods and compositions for targeting Treg cells (2024-07-16),

5. 11952429 - Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers (2024-04-09),

6. 11767367 - Monoclonal antibody neo-201 for the treatment of human carcinomas (2023-09-26),

7. 11572413 - Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers (2023-02-07),

8. 11505604 - Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer (2022-11-22),

9. 11401341 - Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers (2022-08-02),

10. 11345733 - Colon and pancreas cancer specific antigens and antibodies (2022-05-31),

11. 11279768 - Anti-cancer antibodies, combination therapies, and uses thereof (2022-03-22),

12. 11078245 - Colon and pancreas cancer peptidomimetics (2021-08-03),

13. 11001641 - Monoclonal antibody therapy for pancreas cancer (2021-05-11),

14. 10689443 - Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer (2020-06-23),

15. 10533040 - Colon and pancreas cancer peptidomimetics (2020-01-14),

Precision Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of novel antibody-based therapeutics. They focus on the treatment of cancer and other diseases by leveraging advanced antibody technology. With a dedicated team of experts, Precision Biologics strives to advance innovative therapies that improve patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

29 Patents

#18 in Bethesda, MD

#138 in Maryland

#11,219 in US

#21,844 in the World

Bethesda, MD, United States of America

Precision Biologics, Inc.

Forward Citations = 92

16 inventors:

J Andrew Bristol (13 out of 16 patents)

Kwong Y Tsang (12 out of 18 patents)

Myron Arlen (10 out of 15 patents)

4. Xue-Ping Wang (9 out of 10 patents)

5. Judith A Kantor (8 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…